Novel therapies for open-angle glaucoma

F1000Prime Reports

Volumn 6, Issue , 2014, Pages

  Wentz, Scott M ^a   Kim, Nathaniel J ^a   Wang, Jenny ^a   Amireskandari, Annahita ^a   Siesky, Brent ^a   Harris, Alon ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG DELIVERY SYSTEM; HEMODYNAMICS; HUMAN; INTRAOCULAR PRESSURE; NANODEVICE; NERVE FIBER; NEUROPROTECTION; OPEN ANGLE GLAUCOMA; OPHTHALMIC DRUG DELIVERY DEVICE; OPTIC NERVE DISEASE; PATHOPHYSIOLOGY; RETINA GANGLION CELL; RISK FACTOR; SENSOR; TARGET ORGAN; VASCULARIZATION;

EID: 84912020996     PISSN: 20517599     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P6-102     Document Type: Article

References (86)

1. Glaucoma is second leading cause of blindness globally. World Health Organization; 2011. [http://www.who.int/bulletin/volumes/82/11/feature1104/en/]
2. Weinreb RN, Khaw PT: Primary open-angle glaucoma. Lancet 2004, 363:1711-20.
3. Cherecheanu AP, Garhofer G, Schmidl D, Werkmeister R, Schmetterer L: Ocular perfusion pressure and ocular blood flow in glaucoma. Curr Opin Pharmacol 2013, 13:36-42.
4. Czudowska MA, Ramdas WD, Wolfs RC, Hofman A, De Jong PT, Vingerling JR, Jansonius NM: Incidence of glaucomatous visual field loss: a ten-year follow-up from the Rotterdam Study. Ophthalmology 2010, 117:1705-12.
5. Tielsch JM, Katz J, Singh K, Quigley HA, Gottsch JD, Javitt J, Sommer A: A population-based evaluation of glaucoma screening: the Baltimore Eye Survey. Am J Epidemiol 1991, 134:1102-10.
6. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol 1998, 126:487-97.
7. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK, 2nd, Wilson MR, Gordon MO: The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002, 120:701-13; discussion 829-730.
8. Weinreb RN, Lindsey JD: Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest Ophthalmol Vis Sci 2002, 43:716-22.
9. Weinreb RN, Toris CB, Gabelt BT, Lindsey JD, Kaufman PL: Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol 2002, 47(Suppl 1):S53-64.
10. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M: Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002, 120:1268-79.
11. Kaufman PL, Rasmussen CA: Advances in glaucoma treatment and management: outflow drugs. Invest Ophthalmol Vis Sci 2012, 53:2495-500.
12. Rocha-Sousa A, Rodrigues-Araujo J, Gouveia P, Barbosa-Breda J, Azevedo-Pinto S, Pereira-Silva P, Leite-Moreira A: New therapeutic targets for intraocular pressure lowering. ISRN Ophthalmol 2013, 2013:261386.
13. Zhang M, Maddala R, Rao PV: Novel molecular insights into RhoA GTPase-induced resistance to aqueous humor outflow through the trabecular meshwork. Am J Physiol Cell Physiol 2008, 295:C1057-70.
14. Kaufman PL: Marijuana and glaucoma. Arch Ophthalmol 1998, 116:1512-3.
15. Porcella A, Maxia C, Gessa GL, Pani L: The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. Eur J Neurosci 2001, 13:409-12.
16. Ramer R, Hinz B: Cyclooxygenase-2 and tissue inhibitor of matrix metalloproteinases-1 confer the antimigratory effect of cannabinoids on human trabecular meshwork cells. Biochem Pharmacol 2010, 80:846-57.
17. Stamer WD, Golightly SF, Hosohata Y, Ryan EP, Porter AC, Varga E, Noecker RJ, Felder CC, Yamamura HI: Cannabinoid CB(1) receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues. Eur J Pharmacol 2001, 431:277-86.
18. Stumpff F, Boxberger M, Krauss A, Rosenthal R, Meissner S, Choritz L, Wiederholt M, Thieme H: Stimulation of cannabinoid (CB1) and prostanoid (EP2) receptors opens BKCa channels and relaxes ocular trabecular meshwork. Exp Eye Res 2005, 80:697-708.
19. Nucci C, Bari M, Spano A, Corasaniti M, Bagetta G, Maccarrone M, Morrone LA: Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection. Prog Brain Res 2008, 173:451-64.
20. Jampel H: American glaucoma society position statement: marijuana and the treatment of glaucoma. J Glaucoma 2010, 19:75-6.
21. Cedrone C, Mancino R, Cerulli A, Cesareo M, Nucci C: Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects. Prog Brain Res 2008, 173:3-14.
22. Bonomi L, Marchini G, Marraffa M, Bernardi P, Morbio R, Varotto A: Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. Ophthalmology 2000, 107:1287-93.
23. Harris A, Kagemann L, Ehrlich R, Rospigliosi C, Moore D, Siesky B: Measuring and interpreting ocular blood flow and metabolism in glaucoma. Can J Ophthalmol 2008, 43:328-36.
24. Harris A, Rechtman E, Siesky B, Jonescu-Cuypers C, McCranor L, Garzozi HJ: The role of optic nerve blood flow in the pathogenesis of glaucoma. Ophthalmol Clin North Am 2005, 18:345-53, v.
25. Hayreh SS: Blood flow in the optic nerve head and factors that may influence it. Prog Retin Eye Res 2001, 20:595-624.
26. Hulsman CA, Vingerling JR, Hofman A, Witteman JC, de Jong PT: Blood pressure, arterial stiffness, and open-angle glaucoma: the Rotterdam study. Arch Ophthalmol 2007, 125:805-12.
27. Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z: Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 2007, 114:1965-72.
28. Moore D, Harris A, Wudunn D, Kheradiya N, Siesky B: Dysfunctional regulation of ocular blood flow: A risk factor for glaucoma? Clin Ophthalmol 2008, 2:849-61.
29. Caprioli J, Coleman AL: Blood pressure, perfusion pressure, and glaucoma. Am J Ophthalmol 2010, 149:704-12.
30. Galassi F, Sodi A, Ucci F, Renieri G, Pieri B, Baccini M: Ocular hemodynamics and glaucoma prognosis: a color Doppler imaging study. Arch Ophthalmol 2003, 121:1711-15.
31. Hesse RJ: The relationship between progression of visual field defects and retrobulbar circulation in patients with glaucoma. Am J Ophthalmol 1998, 125:566-7.
32. Satilmis M, Orgul S, Doubler B, Flammer J: Rate of progression of glaucoma correlates with retrobulbar circulation and intraocular pressure. Am J Ophthalmol 2003, 135:664-9.
33. Schumann J, Orgul S, Gugleta K, Dubler B, Flammer J: Interocular difference in progression of glaucoma correlates with interocular differences in retrobulbar circulation. Am J Ophthalmol 2000, 129:728-33.
34. Yamazaki Y, Drance SM: The relationship between progression of visual field defects and retrobulbar circulation in patients with glaucoma. Am J Ophthalmol 1997, 124:287-95.
35. Zeitz O, Galambos P, Wagenfeld L, Wiermann A, Wlodarsch P, Praga R, Matthiessen ET, Richard G, Klemm M: Glaucoma progression is associated with decreased blood flow velocities in the short posterior ciliary artery. Br J Ophthalmol 2006, 90:1245-8.
36. Leske MC, Wu SY, Nemesure B, Hennis A: Incident open-angle glaucoma and blood pressure. Arch Ophthalmol 2002, 120:954-9.
37. Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Snyder R: The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol 2001, 119:1819-26.
38. Tielsch JM, Katz J, Sommer A, Quigley HA, Javitt JC: Hypertension, perfusion pressure, and primary open-angle glaucoma. A population-based assessment. Arch Ophthalmol 1995, 113:216-21.
39. Osborne NN, Melena J, Chidlow G, Wood JP: A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: possible implication for the treatment of glaucoma. Br J Ophthalmol 2001, 85:1252-9.
40. Fuchsjager-Mayrl G, Wally B, Georgopoulos M, Rainer G, Kircher K, Buehl W, Amoako-Mensah T, Eichler HG, Vass C, Schmetterer L: Ocular blood flow and systemic blood pressure in patients with primary open-angle glaucoma and ocular hypertension. Invest Ophthalmol Vis Sci 2004, 45:834-9.
41. Garhofer G, Fuchsjager-Mayrl G, Vass C, Pemp B, Hommer A, Schmetterer L: Retrobulbar blood flow velocities in open angle glaucoma and their association with mean arterial blood pressure. Invest Ophthalmol Vis Sci 2010, 51:6652-7.
42. Gherghel D, Orgul S, Gugleta K, Gekkieva M, Flammer J: Relationship between ocular perfusion pressure and retrobulbar blood flow in patients with glaucoma with progressive damage. Am J Ophthalmol 2000, 130:597-605.
43. Choi J, Kim KH, Jeong J, Cho HS, Lee CH, Kook MS: Circadian fluctuation of mean ocular perfusion pressure is a consistent risk factor for normal-tension glaucoma. Invest Ophthalmol Vis Sci 2007, 48:104-11.
44. Sung KR, Lee S, Park SB, Choi J, Kim ST, Yun SC, Kang SY, Cho JW, Kook MS: Twenty-four hour ocular perfusion pressure fluctuation and risk of normal-tension glaucoma progression. Invest Ophthalmol Vis Sci 2009, 50:5266-74.
45. Ullian EM, Barkis WB, Chen S, Diamond JS, Barres BA: Invulnerability of retinal ganglion cells to NMDA excitotoxicity. Mol Cell Neurosci 2004, 26:544-57.
46. Hare W, WoldeMussie E, Lai R, Ton H, Ruiz G, Feldmann B, Wijono M, Chun T, Wheeler L: Efficacy and safety of memantine, an NMDAtype open-channel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey. Surv Ophthalmol 2001, 45(Suppl 3):S284-9; discussion S295-86.
47. Pang IH, Johnson EC, Jia L, Cepurna WO, Shepard AR, Hellberg MR, Clark AF, Morrison JC: Evaluation of inducible nitric oxide synthase in glaucomatous optic neuropathy and pressureinduced optic nerve damage. Invest Ophthalmol Vis Sci 2005, 46:1313-21.
48. Memantine Update: Allergan Reports Fourth Quarterly Operating Results. [http://agn.client.shareholder.com/earningsreleasedetail.cfm?ReleaseID=290764]
49. Foxton RH, Finkelstein A, Vijay S, Dahlmann-Noor A, Khaw PT, Morgan JE, Shima DT, Ng YS: VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma. Am J Pathol 2013, 182:1379-90.
50. Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S: A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol 2011, 151:671-81.
51. Sena DF, Lindsley K: Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev 2013, 2:Cd006539.
52. van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH: Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005, 112:1177-85.
53. Peng CC, Burke MT, Carbia BE, Plummer C, Chauhan A: Extended drug delivery by contact lenses for glaucoma therapy. J Control Release 2012, 162:152-8.
54. Kim HJ, Zhang K, Moore L, Ho D: Diamond nanogel-embedded contact lenses mediate lysozyme-dependent therapeutic release. ACS Nano 2014, 8:2998-3005.
55. Li CC, Chauhan A: Modeling ophthalmic drug delivery by soaked contact lenses. Ind Eng Chem Res 2006, 45:3718-34.
56. Ciolino JB, Stefanescu CF, Ross AE, Salvador-Culla B, Cortez P, Ford EM, Wymbs KA, Sprague SL, Mascoop DR, Rudina SS, Trauger SA, Cade F, Kohane DS: In vivo performance of a drug-eluting contact lens to treat glaucoma for a month. Biomaterials 2014, 35:432-9.
57. Jung HJ, Abou-Jaoude M, Carbia BE, Plummer C, Chauhan A:Glaucoma therapy by extended release of timolol from nanoparticle loaded silicone-hydrogel contact lenses. J Control Release 2013, 165:82-9.
58. Peng CC, Ben-Shlomo A, Mackay EO, Plummer CE, Chauhan A: Drug delivery by contact lens in spontaneously glaucomatous dogs. Curr Eye Res 2012, 37:204-11.
59. Fulgencio Gde O, Viana FA, Ribeiro RR, Yoshida MI, Faraco AG, Cunha-Junior Ada S: New mucoadhesive chitosan film for ophthalmic drug delivery of timolol maleate: in vivo evaluation. J Ocul Pharmacol Ther 2012, 28:350-8.
60. Huang SF, Chen JL, Yeh MK, Chiang CH: Physicochemical properties and in vivo assessment of timolol-loaded poly (D,L-lactide-co-glycolide) films for long-term intraocular pressure lowering effects. J Ocul Pharmacol Ther 2005, 21:445-53.
61. Kashiwagi K, Ito K, Haniuda H, Ohtsubo S, Takeoka S: Development of latanoprost-loaded biodegradable nanosheet as a new drug delivery system for glaucoma. Invest Ophthalmol Vis Sci 2013, 54:5629-37.
62. Macoul KL, Pavan-Langston D: Pilocarpine ocusert system for sustained control of ocular hypertension. Arch Ophthalmol 1975, 93:587-90.
63. Haller JA, Bandello F, Belfort R, Jr., Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM: OZURDEX GENEVA Study Group: Randomized, shamcontrolled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010, 117:1134-46.e1133.
64. Schwartz SG, Flynn HW, Jr.: Fluocinolone acetonide implantable device for diabetic retinopathy. Curr Pharm Biotechnol 2011, 12:347-51.
65. Wang J, Jiang A, Joshi M, Christoforidis J: Drug delivery implants in the treatment of vitreous inflammation. Mediators Inflamm 2013, 2013:780634.
66. Federal Drug Administration: Medical Devices. [http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm312053.htm]
67. Manickavasagam D, Oyewumi MO: Critical assessment of implantable drug delivery devices in glaucoma management. J Drug Deliv 2013, 2013:895013.
68. Diebold Y, Calonge M: Applications of nanoparticles in ophthalmology. Prog Retin Eye Res 2010, 29:596-609.
69. Kim NJ, Harris A, Gerber A, Tobe LA, Amireskandari A, Huck A, Siesky B: Nanotechnology and glaucoma: a review of the potential implications of glaucoma nanomedicine. Br J Ophthalmol 2014, 98:427-31.
70. Zarbin MA, Montemagno C, Leary JF, Ritch R: Nanotechnology in ophthalmology. Can J Ophthalmol 2010, 45:457-76.
71. Natarajan JV, Ang M, Darwitan A, Chattopadhyay S, Wong TT, Venkatraman SS: Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye. Int J Nanomedicine 2012, 7:123-31.
72. Pan T, Brown JD, Ziaie B: An artificial nano-drainage implant (ANDI) for glaucoma treatment. Conf Proc IEEE Eng Med Biol Soc 2006, 1:3174-7.
73. Maleki T, Chitnis G, Park JH, Cantor LB, Ziaie B: Biodegradable microfabricated plug-filters for glaucoma drainage devices. IEEE Trans Biomed Eng 2012, 59:1507-13.
74. Craven ER, Katz LJ, Wells JM, Giamporcaro JE: Cataract surgery with trabecular micro-bypass stent implantation in patients with mild-to-moderate open-angle glaucoma and cataract: two-year follow-up. J Cataract Refract Surg 2012, 38:1339-45.
75. Arriola-Villalobos P, Martinez-de-la-Casa JM, Diaz-Valle D, Fernandez-Perez C, Garcia-Sanchez J, Garcia-Feijoo J: Combined iStent trabecular micro-bypass stent implantation and phacoemulsification for coexistent open-angle glaucoma and cataract: a long-term study. Br J Ophthalmol 2012, 96:645-9.
76. Kent C: Three Stents in the Glaucoma Pipeline. Review of Ophthalmology; 2012. [http://www.reviewofophthalmology.com/content/t/glaucoma/c/33743/]
77. Simon G: A Suprachoidal Gold Shunt for Glaucoma. European Ophthalmic Review 2008: 42-4.
78. Mansouri K,Weinreb R: Continuous 24-hour intraocular pressure monitoring for glaucoma-time for a paradigm change. Swiss Med Wkly 2012, 142:w13545.
79. Agnifili L, Mastropasqua R, Frezzotti P, Fasanella V, Motolese I, Pedrotti E, Iorio AD, Mattei PA, Motolese E, Mastropasqua L: Circadian intraocular pressure patterns in healthy subjects, primary open angle and normal tension glaucoma patients with a contact lens sensor. Acta Ophthalmol 2014, [Epub ahead of print].
80. De Smedt S, Mermoud A, Schnyder C: 24-hour intraocular pressure fluctuation monitoring using an ocular telemetry Sensor: tolerability and functionality in healthy subjects. J Glaucoma 2012, 21:539-44.
81. Gravitz L: Glaucoma Test in a Contact Lens. MIT Technology Review; 2010. [http://www.technologyreview.com/news/418247/glaucoma-test-in-a-contact-lens/]
82. Lorenz K, Korb C, Herzog N, Vetter JM, Elflein H, Keilani MM, Pfeiffer N: Tolerability of 24-hour intraocular pressure monitoring of a pressure-sensitive contact lens. J Glaucoma 2013, 22:311-6.
83. SENSIMED Triggerfish® provides an automated recording of continuous ocular dimensional changes over 24 hours. 2014. [http://www.sensimed.ch/en/sensimed-triggerfish/sensimed-triggerfish.html]
84. Chen P, Rodger D, Saati S: Microfabricated Implantable Parylene-Based Wireless Passive Intraocular Pressure Sensors. J Microelectromech Syst 2008, 17:1342-51.
85. Sensor in eye could track pressure changes, monitor for glaucoma. [http://www.washington.edu/news/2014/06/16/sensor-ineye-could-track-pressure-changes-monitor-for-glaucoma/]
86. Intraocular Pressure Sensor. 2014. [http://www.launchpnt.com/portfolio/biomedical/intraocular-pressure-sensor/]